Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Evidence based guidelines. Diagnosis and management of Guillain-Barré syndrome in ten steps].
Leonhard SE, Mandarakas MR, de Assis Aquino Gondim F, Bateman K, Brito Ferreira ML, Cornblath DR, Van Doorn PA, Dourado ME, Hughes RAC, Islam B, Kusunoki S, Pardo CA, Reisin R, Sejvar JJ, Shahrizaila N, Soares C, Umapathi T, Wang Y, Yiu EM, Willison HJ, Jacobs BC. Leonhard SE, et al. Among authors: cornblath dr. Medicina (B Aires). 2021;81(5):817-836. Medicina (B Aires). 2021. PMID: 34633957 Free article. Spanish.
Serum antibodies to gangliosides in Guillain-Barré syndrome.
Ilyas AA, Willison HJ, Quarles RH, Jungalwala FB, Cornblath DR, Trapp BD, Griffin DE, Griffin JW, McKhann GM. Ilyas AA, et al. Among authors: cornblath dr. Ann Neurol. 1988 May;23(5):440-7. doi: 10.1002/ana.410230503. Ann Neurol. 1988. PMID: 3133978
Guillain-Barré syndrome: the evolution of therapy.
Cornblath DR, Hughes RA. Cornblath DR, et al. J Neurol. 1994 May;241(6):404-5. doi: 10.1007/BF02033360. J Neurol. 1994. PMID: 7931438 Clinical Trial. No abstract available.
Preceding infections, immune factors, and outcome in Guillain-Barré syndrome.
Hadden RD, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, Weishaupt A, Cornblath DR, Swan AV, Hughes RA, Toyka KV; Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Hadden RD, et al. Among authors: cornblath dr. Neurology. 2001 Mar 27;56(6):758-65. doi: 10.1212/wnl.56.6.758. Neurology. 2001. PMID: 11274311 Clinical Trial.
Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology.
Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, Sladky JT, Stevens JC; Quality Standards Subcommittee of the American Academy of Neurology. Hughes RA, et al. Among authors: cornblath dr. Neurology. 2003 Sep 23;61(6):736-40. doi: 10.1212/wnl.61.6.736. Neurology. 2003. PMID: 14504313
Supportive care for patients with Guillain-Barré syndrome.
Hughes RA, Wijdicks EF, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Sladky JT, Barohn RJ, Stevens JC; Multidisciplinary Consensus Group. Hughes RA, et al. Among authors: cornblath dr. Arch Neurol. 2005 Aug;62(8):1194-8. doi: 10.1001/archneur.62.8.1194. Arch Neurol. 2005. PMID: 16087757
273 results